A target-oriented algorithm for citrate-calcium anticoagulation in clinical practice

Blood Purification

Volumn 36, Issue 2, 2013, Pages 136-145

  Strobl, Karin ^a   Hartmann, Jens ^a   Wallner, Manfred ^b   Brandl, Martin ^a   Falkenhagen, Dieter ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b Klinikum Wels Grieskirchen GmbH   (Austria)

Author keywords

Anticoagulation; Blood purification; Clinical study; Extracorporeal therapies; Haemodialysis; Regional citrate anticoagulation

Indexed keywords

CALCIUM; CALCIUM CHLORIDE; CALCIUM ION; CITRATE TRISODIUM; ELECTROLYTE; HEPARIN; MAGNESIUM;

ACID BASE BALANCE; ADULT; ALGORITHM; ALKALOSIS; ANTICOAGULATION; ARTICLE; BLOOD; BLOOD CELL COUNT; BLOOD CLOTTING PARAMETERS; BLOOD PH; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PRACTICE; DIALYSATE; DIALYSIS FILTER; END STAGE RENAL DISEASE; FEMALE; FILTER; HEMATOLOGY ANALYZER; HEMODIALYSIS; HEMODIALYSIS MACHINE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; MALE; PRIORITY JOURNAL; PURIFICATION; REGIONAL CITRATE ANTICOAGULATION;

ADULT; ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION; CALCIUM; CALCIUM CITRATE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84889648494     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000355012     Document Type: Article

References (47)

1. Tobe SW, Aujla P, Walele AA, Oliver MJ, Naimark DM, Perkins NJ, Beardsall M: A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003; 18: 121-129.
2. Swartz R, Pasko D, OToole J, Starmann B: Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004; 61: 134-143.
3. Balik M, Waldauf P, Plasil P, Pachl J: Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif 2005; 23: 325-329.
4. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367.
5. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T: Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care 2005; 20: 155-161.
6. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate versus heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265.
7. Hartmann J, Strobl K, Falkenhagen D: Anticoagulation in combined membrane/adsorption systems. Prilozi 2008; 29: 39-49.
8. Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH: Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996; 7: 234-241.
9. Gritters M, Grooteman MP, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nube MJ: Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153-159.
10. Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ: Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997; 12: 1387-1393.
11. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C: The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004; 17: 819-825.
12. Dhondt A, Vanholder R, Tielemans C, Glorieux G, Waterloos MA, De Smet R, Lameire N: Effect of regional citrate anticoagulation on leukopenia, complement activation, and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes. Nephron 2000; 85: 334-342.
13. Samuelsson O, Amiral J, Attman PO, Bennegard K, Bjorck S, Larsson G, Tengborn L: Heparin-induced thrombocytopenia during continuous haemofiltration. Nephrol Dial Transplant 1995; 10: 1768-1771.
14. Palsson R, Niles JL: Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55: 1991-1997.
15. Ridel C, Mercadal L, Bene B, Hamani A, Deray G, Petitclerc T: Regional citrate anticoagulation during hemodialysis: a simplified procedure using Duocart biofiltration. Blood Purif 2005; 23: 473-480.
16. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS: Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis 1996; 27: 519-524.
17. Lohr JW, Slusher S, Diederich DA: Regional citrate anticoagulation for hemodialysis following cardiovascular surgery. Am J Nephrol 1988; 8: 368-372.
18. Van der Voort PH, Postma SR, Kingma WP, Boerma EC, Van Roon EN: Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin. Int J Artif Organs 2006; 29: 559-563.
19. Mehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981.
20. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552.
21. Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26: 232-239.
22. Szamosfalvi B, Frinak S, Yee J: Automated regional citrate anticoagulation: technological barriers and possible solutions. Blood Purif 2010; 29: 204-209.
23. Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G: Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 2005; 45: 557-564.
24. Clark JA, Schulman G, Golper TA: Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. Clin J Am Soc Nephrol 2008; 3: 736-742.
25. Tolwani A, Wille KM: Citrate-based replacement solutions with continuous venovenous hemofiltration: not as simple as it sounds. Am J Kidney Dis 2006; 47: 1086, author reply 1086-1087.
26. Whitfield LR, Levy G: Permeability of human and rat red blood cells to citrate. Thromb Res 1981; 21: 681-684.
27. Hartmann J, Strobl K, Fichtinger U, Schildbock C, Falkenhagen D: In vitro investigations of citrate clearance with different dialysis filters. Int J Artif Organs 2012; 35: 352-359.
28. Buturovic-Ponikvar J, Cerne S, Gubensek J, Ponikvar R: Regional citrate anticoagulation for hemodialysis: calcium-free vs. calcium containing dialysate-a randomized trial. Int J Artif Organs 2008; 31: 418-424.
29. Meier-Kriesche HU, Gitomer J, Finkel K, Du-Bose T: Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752.
30. Brandl M, Hartmann J, Strobl K, Falkenhagen D: Verfahren zum Erfassen der Ionenkonzentration bei Citrat-antikoagulierter extrakorporalen Blutreinigung, Patentanmeldung. Osterreichische Patentanmeldung, AZ1368/2007, 2008.
31. Brandl M, Strobl K, Hartmann J, Kellner K, Posnicek T, Falkenhagen D: A target-orientated algorithm for regional citrate-calcium anticoagulation in extracorporeal therapies. Blood Purif 2012; 33: 7-20.
32. Falkenhagen D, Thijssen S, Brandl M, Hartmann J, Strobl K, Wallner M: Correlation between ACT (activated clotting time) and iCa (ionized calcium) in RDT-patients. EDTAERA Congress, Prague, 2011.
33. Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH: Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med 2006; 44: 962-966.
34. Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer HH: A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acidbase status. Crit Care Med 2009; 37: 2018-2024.
35. Davenport A, Tolwani A: Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to intensive care unit. Nephrol Dialysis Transplant Plus 2009; 2: 439-447.
36. Kozik-Jaromin J, Nier V, Heemann U, Kreymann B, Bohler J: Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant 2009; 24: 2244-2251.
37. Chadha V, Garg U, Warady BA, Alon US: Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 2002; 17: 819-824.
38. Bauer E, Derfler K, Joukhadar C, Druml W: Citrate kinetics in patients receiving longterm hemodialysis therapy. Am J Kidney Dis 2005; 46: 903-907.
39. Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A: Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450-2455.
40. Kreuzer M, Ahlenstiel T, Kanzelmeyer N, Ehrich JH, Pape L: Management of regional citrate anticoagulation in pediatric high-flux dialysis: activated coagulation time versus post-filter ionized calcium. Pediatr Nephrol 2010; 25: 1305-1310.
41. Falkenhagen D, Thijssen S, Brandl M, Hartmann J, Strobl K: Relationship between ionized calcium concentration and activated clotting time in citrate anticoagulated blood (abstract)]. J Am Soc Nephrol 2010; 21: 434A.
42. Falkenhagen D, Brandl M, Fichtinger U, Kellner K, Hartmann J, Posnicek T, Schildboeck C, Strobl K: Demonstration of an advanced citrate anticoagulation technology-first clinical experience: renal diseases and biotechnology for blood purification. Empress International Convention Centre, 2009, pp 42-43.
43. Opatrny K, Richtrova P, Polanska K, Wirth J, Sefrna F, Brandl M, Falkenhagen D: Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis. Artif Organs 2007; 31: 200-207.
44. Hartmann J, Strobl K, Fichtinger U, Falkenhagen D: Citrate anticoagulation and activation of the complement system (abstract). Int J Artif Organs 2006; 29: 538.
45. Hartmann J, Strobl K, Fichtinger U, Falkenhagen D: Optimization of citrate anticoagulation (abstract). Int J Artif Organs 2007; 30: 742.
46. Heil W, Koberstein R, Zawta B (eds): Referenzbereich fur Kinder und Erwachsene. Mannheim, Boehringer Mannheim, 1998.
47. Tompkins D, Toffaletti J: Enzymic determination in serum and urine, with use of the Worthington ultrafree device. Clin Chem 1982; 28: 192-195.